Conflict of interest: Issam D. Moussa, MD: No conflict; Lloyd W. Klein, MD: No conflict; Binita Shah, MD: Research grant - Guerbet; Roxana Mehran, MD: Consultant: Maya Medical (Consultant) Astra Zeneca, Merck, Abbott Vascular, Regado Biosciences, Janssen Pharma; Grants or Research Support: Lilly/Daiichi Sankyo, The Medicines Company, BMS/Sanofi; Michael J. Mack, MD: No conflict; Emmanouil S. Brilakis, MD: Speaker bureau: St Jude Medical, Medtronic and Terumo; Research grant: Guerbet; Spouse is an employee of Medtronic; John P. Reilly, MD: Consultant: Gilead; Speakers Bureau: Astra/Zeneca and Daichii/Lilly; Gilbert Zoghbi, MD: No conflict; Elizabeth Holper, MD: Speakers Bureau: Boston Scientific; Gregg W. Stone, MD: Consultant: Boston Scientific, Eli Lilly, Daiichi Sankyo and Astra Zeneca.
Coronary Artery Disease
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)
Article first published online: 16 OCT 2013
Copyright © 2013 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 83, Issue 1, pages 27–36, 1 January 2014
How to Cite
Moussa, I. D., Klein, L. W., Shah, B., Mehran, R., Mack, M. J., Brilakis, E. S., Reilly, J. P., Zoghbi, G., Holper, E. and Stone, G. W. (2014), Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Cathet. Cardiovasc. Intervent., 83: 27–36. doi: 10.1002/ccd.25135
- Issue published online: 18 DEC 2013
- Article first published online: 16 OCT 2013
- Accepted manuscript online: 25 JUL 2013 06:41PM EST
- Manuscript Accepted: 13 JUL 2013
- Manuscript Received: 12 JUL 2013
- 3Third universal definition of myocardial infarction. Circulation 2012;60:1581–1598., , , et al.
- 5The different mechanisms of periprocedural myocardial infarction and their impact on in-hospital outcome. J Invasive Cardiol 2012;24:655–660., , , et al.
- 10A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. JACC Cardiovasc Interv 2011;4:645–653., , , et al.
- 18Evaluation of drug eluting stents and ischemic events (EVENT) registry investigators. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the evaluation of drug eluting stents and ischemic events registry. Circulation 2008;118:632–638., , , et al.
- 19Universal definition of myocardial infarction classification system and the risk of cardiovascular death: Observations from the TRITON-TIMI 38 trial (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Circulation 2012;125:577–583., , , et al.
- 28Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: A collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). Circulation 2012;125:568–576., , , et al.
- 34Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: Insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006;114:662–669., , , et al.
- 38Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: Results from four large clinical trials. Eur Heart J 2007;28;425–432., , , et al.
- 46The prognostic value of troponin release after adult cardiac surgery—A meta-analysis. Eur J Cardiothorac Surg 2010;37:399–406., , , et al.
- 47Cardiac troponin I levels after cardiac surgery as predictor for in-hospital mortality. J Thorac Cardiovasc Surg 2009;10:413–416., , .
- 582011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44–e122., , , et al.
- 65Quality assessment and improvement in interventional cardiology. A position statement of the society of cardiovascular angiography and interventions. I. Standards for quality assessment and improvement in interventional cardiology. Cath Cardiovasc Int 2011;77:927–935., , , et al.
- 73Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: Implications for early discharge after coronary intervention. J Am Coll Cardiol 1999;34:663–671., , , et al.
- 77Death following creatine kinase-MB elevation after coronary intervention: Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205–1210., , , et al.